Atezolizumab Extends Survival for Breast Cancer.

  • Published 2017 in Cancer discovery


The anti-PD-L1 drug atezolizumab produced durable responses among 10% of patients with triple-negative breast cancer in a large phase I trial presented at the American Association for Cancer Research Annual Meeting 2017. The therapy proved safe, with the highest response rates seen in women who received the drug as a first-line therapy and in those with… (More)
DOI: 10.1158/2159-8290.CD-NB2017-053


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics